SubsidieMeestersNovel therapeutic platform for aggressive lymphoma: NanoLymphoma
NanoLymphoma aims to develop a novel therapeutic platform using nanofilaments to cluster multiple lymphoma targets, enhancing tumor cell death and providing a promising treatment for aggressive B-cell lymphoma.
Projectdetails
Introduction
Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line treatment in patients with B-cell lymphoma. However, diffuse large B-cell lymphoma (DLBCL), the most common and aggressive form of B-cell lymphoma worldwide, is still incurable in 40% of patients.
Prognosis and Need for Novel Therapies
These patients have poor prognosis due to treatment failure or relapse upon therapy with CD20-antibodies (260,000 mortalities worldwide in 2020). Thus, there is an urgent need for novel therapies to overcome resistance and enhance anti-tumor activities in patients with aggressive B-cell lymphoma.
Development of NanoLymphoma
We developed nanofilaments that can efficiently cluster multiple lymphoma membrane targets (CD20, and new targets: CD22, CD37) to induce potent tumor cytotoxicity. This new therapeutic platform ("NanoLymphoma") represents a powerful strategy since this approach is independent from genetic cancer subtypes and is broadly applicable in molecular heterogeneous B-cell lymphoma subtypes.
Evaluation and Validation
NanoLymphoma will evaluate and validate the technical and commercial feasibility of its new therapeutic platform to target human lymphoma cells and prepare for clinical translation to patients with DLBCL.
Objectives of NanoLymphoma
NanoLymphoma will:
- Show that clustering of therapeutic targets on the surface of tumor cells potently induces tumor cell death.
- Perform market and business case analyses to ensure commercial feasibility and entry to market through Simmunext Biotherapeutics.
Expected Outcomes
NanoLymphoma is expected to outperform conventional anti-CD20 antibody treatment in patients with aggressive lymphoma.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 28-2-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC Proof of... | € 150.000 | 2023 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
Lectibodies to Eliminate TumoursThis project aims to develop lectibodies for targeted delivery of therapeutics to neuroblastoma by harnessing GSL-binding proteins, potentially revolutionizing cancer treatment. | ERC Proof of... | € 150.000 | 2022 | Details |
Novel T cell therapies against lymphocytic leukaemiaCATCH aims to enhance T-cell activation in chronic lymphocytic leukaemia using CAR-T and tri-specific antibodies, while assessing commercial feasibility and developing a business strategy. | ERC Proof of... | € 150.000 | 2022 | Details |
Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapiesThis project aims to enhance LNP-mRNA nanomedicine efficacy for advanced breast cancer by improving endosomal escape through nanoscale engineering and tailored formulations. | ERC Starting... | € 1.844.248 | 2024 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.
Lectibodies to Eliminate Tumours
This project aims to develop lectibodies for targeted delivery of therapeutics to neuroblastoma by harnessing GSL-binding proteins, potentially revolutionizing cancer treatment.
Novel T cell therapies against lymphocytic leukaemia
CATCH aims to enhance T-cell activation in chronic lymphocytic leukaemia using CAR-T and tri-specific antibodies, while assessing commercial feasibility and developing a business strategy.
Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapies
This project aims to enhance LNP-mRNA nanomedicine efficacy for advanced breast cancer by improving endosomal escape through nanoscale engineering and tailored formulations.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models. | EIC Accelerator | € 2.499.999 | 2024 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Accelerated Discovery Nanobody PlatformThe ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing. | EIC Pathfinder | € 3.315.441 | 2024 | Details |
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemiaThe project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes. | EIC Transition | € 2.497.500 | 2023 | Details |
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Accelerated Discovery Nanobody Platform
The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
The project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes.